Regeneron CEO: Anticipating PCSK9 launch, but worried about pricing debate

Regeneron ($REGN) is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. And in hopes of approval, it's working on launch plans with partner Sanofi ($SNY). But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power. Report

Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.